keyword
sarcoidosi
antimicrobi
infecti
antigen
grow
bodi
literatur
support
role
infecti
antigen
particular
mycobacteria
propionibacteria
sarcoidosi
pathogenesi
immunolog
studi
reveal
mycobacteri
virul
factor
target
immun
respons
sarcoidosi
diagnost
bronchoalveolar
lavag
bal
recent
case
report
clinic
trial
emerg
report
efficaci
antimicrobi
therapi
cutan
pulmonari
sarcoidosi
although
studi
conclus
demonstr
efficaci
endpoint
associ
sarcoidosi
morbid
mortal
forc
vital
capac
fvc
lindsay
j
celada
phd
charlen
hawkin
phd
b
wonder
p
drake
phd
b
sarcoidosi
granulomat
diseas
unknown
etiolog
commonli
involv
lung
skin
lymph
node
eye
granulomat
inflamm
initi
infecti
agent
fungi
mycobacterium
tuberculosi
mtb
noninfecti
agent
beryllium
chronic
beryllium
diseas
analysi
sarcoidosi
epidemiolog
suggest
infecti
agent
role
sarcoidosi
pathogenesi
investig
case
control
etiolog
studi
sarcoidosi
observ
posit
associ
sarcoidosi
risk
certain
occup
agricultur
employ
exposur
insecticid
moldi
environ
anoth
studi
note
hospit
admiss
african
american
sarcoidosi
south
carolina
increas
proxim
atlant
ocean
unifi
factor
environment
geograph
report
possibl
exposur
microbi
bioaerosol
natur
water
water
distribut
system
biofilm
pipe
peat
pot
soil
water
droplet
equip
bronchoscop
cathet
moldi
build
natur
habitat
environment
opportunist
mycobacteria
aerosol
environment
opportunist
mycobacteria
associ
develop
granulomat
diseas
mycobacteri
origin
hypersensit
pneumon
inabl
identifi
microorgan
histolog
stain
cultur
microorgan
patholog
tissu
continu
one
strongest
argument
potenti
role
infecti
agent
sarcoidosi
pathogenesi
molecular
analysi
continu
grow
sensit
specif
current
cultur
stain
method
known
identifi
less
current
microbi
commun
present
within
human
biolog
specimen
advanc
molecular
techniqu
deep
sequenc
technolog
also
demonstr
success
identif
novel
microorgan
patholog
tissu
easili
identifi
tradit
method
molecular
analysi
patholog
tissu
microbi
nucleic
acid
protein
serv
altern
mean
identifi
put
infecti
agent
polymeras
chain
reaction
pcr
use
identifi
etiolog
agent
whippl
diseas
tropheryma
whippelii
well
novel
coronaviru
agent
sever
acut
respiratori
syndrom
grow
scientif
interest
involv
defin
microbi
commun
within
distinct
diseas
microbiom
analysi
microbiom
analysi
perform
upper
lower
airway
subject
interstiti
lung
diseas
includ
idiopath
interstiti
pneumonia
iip
noniip
sarcoidosi
well
pneumocysti
jiroveci
pneumonia
healthi
control
microbiota
lower
airway
major
patient
primarili
consist
prevotellacea
streptococcacea
acidaminococcacea
b
divers
measur
reveal
signific
differ
airway
microbiota
composit
differ
group
patient
conclud
iip
noniip
sarcoidosi
associ
disord
airway
microbiota
pathogen
role
commens
diseas
process
therefor
unlik
target
molecular
approach
microbi
pathogen
sarcoidosi
granuloma
strongli
support
propionibacteria
andor
mycobacteria
role
sarcoidosi
pathogenesi
japanes
research
report
molecular
evid
propionibacterium
acn
dna
sarcoidosi
specimen
although
dna
could
also
isol
control
specimen
distinct
lie
quantit
differ
p
acn
dna
sarcoidosi
control
number
genom
p
acn
bal
cell
correl
serum
angiotensinconvert
enzym
level
percentag
macrophag
bal
fluid
patient
sarcoidosi
signific
differ
detect
p
granulosum
control
murin
model
sarcoidosi
pathogenesi
success
develop
use
heatkil
propionibacteria
intratrach
challeng
model
demonstr
contribut
tolllik
receptor
tlr
develop
polar
h
immun
respons
anoth
studi
confirm
role
p
acnesspecif
sarcoidosi
immun
respons
demonstr
p
acnesinduc
granulomat
pulmonari
inflamm
markedli
attenu
mice
compar
wildtyp
anim
recent
metaanalysi
involv
casecontrol
studi
p
acn
associ
sarcoidosi
reveal
significantli
elev
sarcoidosi
risk
odd
ratio
ci
investig
independ
laboratori
worldwid
also
report
molecular
evid
support
signific
associ
mycobacteria
sarcoidosi
one
studi
report
evid
mycobacteri
ribosom
rna
rrna
rna
polymeras
b
sarcoidosi
granuloma
none
control
p
chisquar
sequenc
analysi
rrna
rpob
amplicon
reveal
presenc
novel
mycobacterium
genet
similar
mtb
complex
posit
ident
use
matrixassist
laser
desorpt
ioniz
timeofflight
mass
spectrometri
song
colleagu
found
mtb
katg
peptid
sarcoidosi
specimen
compar
control
specimen
p
situ
hybrid
local
mtb
katg
rrna
dna
insid
sarcoidosi
granuloma
analysi
polish
sarcoidosi
lymph
node
reveal
mtb
complex
heat
shock
protein
hsp
hsp
hsp
molecular
analysi
american
sarcoidosi
granuloma
also
reveal
presenc
nucleic
acid
mycobacteri
virul
factor
superoxid
dismutas
soda
sarcoidosi
specimen
compar
control
p
sequenc
analysi
amplicon
demonstr
close
posit
ident
mtb
complex
yet
genet
distinct
dna
mycobacteri
hsp
detect
cutan
lesion
chines
sarcoidosi
patient
absent
control
specimen
sequenc
analysi
consist
mtb
chelona
gordona
anoth
studi
report
abil
realtim
pcr
analysi
quantit
differenti
sarcoidosi
tuberculosi
use
receiv
oper
characterist
curv
realtim
pcr
analysi
independ
laboratori
demonstr
viabl
mycobacteria
present
within
sarcoidosi
granuloma
present
sensit
acidfast
bacilli
histolog
stain
futur
molecular
effort
delin
identifi
nucleic
acid
protein
reflect
activ
replic
organ
persist
protein
equal
import
modal
delin
infecti
agent
role
idiopath
diseas
assess
immun
respons
microbi
protein
presenc
humor
cellular
respons
microbi
antigen
insight
method
assess
exposur
infecti
agent
increas
lymphocyt
prolifer
induc
p
acn
report
patient
activ
sarcoidosi
howev
respons
correl
clinic
roentgenograph
physiolog
bal
find
regard
diseas
sever
sarcoidosi
h
h
immun
respons
viabl
p
acn
significantli
differ
healthi
control
recent
report
immun
respons
mycobacteria
also
report
along
detect
peptid
fragment
consist
katg
protein
within
sarcoidosi
granuloma
exist
humor
immun
respons
mycobacteri
katg
protein
demonstr
sarcoidosi
patient
song
colleagu
note
igg
antibodi
recombin
mtb
katg
sera
sarcoidosi
patient
compar
sera
purifi
protein
derivativeneg
control
p
sarcoidosi
character
polar
cell
h
immunophenotyp
identif
h
cellular
immun
respons
mycobacteri
katg
peptid
sarcoidosi
peripher
blood
mononuclear
cell
pbmc
suggest
sarcoidosi
immun
respons
may
mycobacteri
virul
factor
distinct
cellular
recognit
pattern
virul
factor
antigen
differenti
mycobacteri
speci
exampl
patient
infect
mtb
recogn
distinct
peptid
infect
lepra
investig
sarcoidosi
immun
respons
pattern
confirm
pattern
detect
distinct
patient
infect
mtb
lepra
anoth
report
demonstr
system
h
immun
respons
multipl
mycobacteri
virul
factor
sarcoidosi
patient
respons
multipl
secret
protein
also
multipl
epitop
within
given
protein
find
analog
observ
patient
activ
bacteri
infect
dual
molecular
immunolog
analysi
sarcoidosi
specimen
mycobacteri
virul
factor
soda
demonstr
nucleic
acid
sequenc
closest
mtb
yet
distinct
translat
sequenc
peptid
stimul
sarcoidosi
pbmc
result
reproduct
sarcoidosi
h
immunophenotyp
mycobacteri
protein
soda
virul
factor
confer
pathogen
mycobacterium
speci
demonstr
protein
secret
system
requir
optim
secret
soda
katg
protein
synthes
without
sec
signal
sequenc
function
detoxifi
reactiv
oxygen
intermedi
gener
host
macrophag
part
special
secret
system
contribut
virul
pathogen
mycobacteria
counter
oxid
attack
host
confer
abil
surviv
within
host
macrophag
addit
tcell
immun
respons
mtb
katg
detect
sarcoidosi
bal
comparison
immun
respons
mycobacteri
katg
whole
protein
american
swedish
sarcoidosi
subject
reveal
differ
despit
distinct
patient
phenotyp
genet
prognost
characterist
also
demonstr
although
h
immun
respons
present
system
katgreact
cell
preferenti
accumul
lung
indic
compartment
respons
patient
without
fgren
syndrom
similar
frequenc
katgspecif
interferongammaexpress
peripher
cell
studi
also
demonstr
circul
katgreact
cell
found
chronic
activ
sarcoidosi
patient
inact
diseas
loss
immun
respons
mycobacteri
virul
factor
resolut
tuberculosi
also
observ
anoth
report
demonstr
immun
respons
mycobacteri
virul
factor
present
sarcoidosi
diagnost
bal
induct
innat
immun
contribut
polar
h
immun
respons
recognit
significantli
absent
bal
fluid
cell
patient
lung
diseas
includ
infecti
granulomat
diseas
detect
immun
respons
katg
soda
confirm
exposur
sarcoidosi
patient
pathogen
mycobacteri
speci
protein
typic
secret
stage
activ
mycobacteri
replic
compar
express
protein
express
mycobacteria
latent
state
immunolog
analysi
perform
date
provid
mechan
indepth
analysi
sarcoidosi
pathogenesi
protein
use
delin
immunolog
pathway
contribut
sarcoidosi
resolut
diseas
progress
report
amyloid
precursor
protein
serum
amyloid
saa
strikingli
abund
sarcoidosi
tissu
predominantli
nonfibrillar
form
local
epithelioid
granuloma
saa
detect
numer
pulmonari
infect
tuberculosi
nontubercul
mycobacteria
infect
leprosi
comparison
quantit
immunohistochemistri
show
extent
distribut
saa
sarcoidosi
significantli
lower
diseas
granulomat
inflamm
chen
moller
elabor
concept
chronic
stimul
innat
immun
system
disaggreg
host
protein
saa
within
granuloma
microbi
infect
induc
hyperimmun
h
immun
respons
microbi
antigen
absenc
ongo
infect
saa
level
reduc
pulmonari
tuberculosi
subject
initi
antimicrobi
therapi
addit
antibodi
autoantigen
zinc
finger
protein
mitochondri
ribosom
protein
identifi
sarcoidosi
bal
serum
high
interindividu
heterogen
note
use
pulmonari
cell
patient
hladr
molecul
affin
purifi
bound
peptid
acid
elut
peptidi
separ
reversedphas
highperform
liquid
chromatographi
analyz
liquid
chromatographymass
spectrometri
result
identif
autoantigen
vimentin
atp
synthas
data
support
immun
respons
selfantigen
present
local
system
site
sarcoidosi
subject
investig
sarcoidosi
immun
function
tcell
receptor
tcr
stimul
reveal
signific
distinct
healthi
control
presenc
chronic
immun
stimul
due
persist
microbi
antigen
report
reduc
tcell
function
sarcoidosi
lymphocyt
also
character
reduc
cytokin
express
prolif
capac
well
upregul
inhibitori
receptor
program
immunolog
phenomena
associ
elev
antigen
burden
defin
wherri
colleagu
tcell
exhaust
occur
result
chronic
antigen
stimul
durat
antigen
exposur
result
gradual
reduct
cell
abil
optim
respond
tcr
stimul
although
healthi
cell
produc
high
level
cytokin
exhibit
high
level
prolifer
low
level
apoptosi
respons
antigen
exhaust
cell
gradual
lose
normal
function
longer
respond
antigen
instead
undergo
apoptosi
tcr
activ
upregul
cell
play
signific
role
acquisit
exhaust
phenotyp
inhibitori
coreceptor
signal
ligand
function
modul
toler
self
antigen
limit
robust
adapt
immun
respons
foreign
antigen
exhaust
cell
express
high
level
correl
well
systemat
loss
cellular
function
recent
find
upregul
dysfunct
sarcoidosi
cell
well
cell
granulomat
diseas
character
microbi
antigen
mtb
schistosomiasi
suggest
phenotyp
could
result
persist
antigen
exposur
fig
tabl
upregul
receptor
reduc
prolif
capac
sarcoidosi
bal
peripher
cell
recent
report
restor
sarcoidosi
tcell
prolif
capac
healthi
control
level
appar
pathway
blockad
variou
mechan
interfer
tcell
prolifer
well
describ
report
inhibit
tcell
prolifer
block
cell
cycl
progress
suppress
transcript
substrat
recognit
compon
ubiquitin
ligas
complex
scf
bind
degrad
cyclindepend
kinas
cdk
inhibitor
therebi
allow
continu
cell
cycl
cell
cycl
impedi
therefor
prolifer
hindranc
shown
result
erk
pathway
inactiv
inhibit
tcell
prolifer
correl
increas
avail
repress
cdkactiv
phosphatas
engag
also
demonstr
attenu
tcr
signal
prevent
pkcq
activ
report
upregul
particularli
import
associ
emerg
human
lymphotrop
virus
epsteinbarr
viru
cytomegaloviru
virus
associ
sarcoidosi
pathogenesi
public
molecular
immunolog
support
role
microorgan
sarcoidosi
pathogenesi
fungi
propionibacteria
mycobacteria
increas
number
case
report
clinic
trial
regard
efficaci
antimicrobi
therapi
numer
prior
report
tetracyclin
particular
doxycyclin
minocyclin
publish
subject
cutan
sarcoidosi
although
minocyclin
antimicrobi
effect
p
acn
mechan
action
thought
immunomodulatori
recent
report
efficaci
clarithromycin
efficaci
propionibacteria
mycobacteria
report
japanes
woman
system
sarcoidosi
conclus
delin
mechan
action
pend
fungal
antigen
also
report
contribut
sarcoidosi
pathogenesi
clinic
radiograph
improv
administr
antifung
therapi
posaconazol
mgd
ketoconazol
mgd
without
corticosteroid
report
slovenian
sarcoidosi
patient
investig
conduct
openlabel
patientprefer
trial
steroid
methylprednisolon
mgkg
antifung
agent
posaconazol
mgd
ketoconazol
mgd
steroidsantifung
agent
signific
clinic
radiograph
improv
detect
antifung
group
also
report
reduct
diseas
recurr
among
antifung
therapi
studi
limit
includ
lack
random
well
conduct
doubleblind
fashion
two
clinic
trial
regard
efficaci
antimycobacteri
therapi
sarcoidosi
pathogenesi
report
doubl
blind
placebocontrol
investig
antimycobacteri
regimen
consist
concomit
levofloxacin
ethambutol
azithromycin
rifampin
clear
compar
placebo
conduct
subject
cutan
sarcoidosi
intentiontotreat
analysi
cleartreat
group
mean
sd
decreas
lesion
diamet
mm
compar
increas
mm
placebotr
group
abbrevi
e
epidemiolog
immunolog
molecular
p
clear
group
signific
reduct
granuloma
burden
experienc
mean
sd
declin
mm
lesion
sever
compar
declin
mm
placebo
group
p
observ
clinic
reduct
present
followup
period
transcriptom
analysi
sarcoidosi
cell
reveal
revers
pathway
associ
diseas
sever
enhanc
tcell
function
tcr
stimul
addit
openlabel
investig
regimen
conduct
pulmonari
sarcoidosi
subject
chronic
pulmonari
sarcoidosi
patient
fvc
predict
enrol
primari
efficaci
endpoint
chang
absolut
fvc
baselin
complet
therapi
secondari
endpoint
chang
function
capac
measur
six
minut
walk
distanc
qualityoflif
assess
measur
st
georg
respiratori
questionnair
sgrq
patient
enrol
complet
week
therapi
complet
week
therapi
clear
regimen
associ
fvc
increas
l
week
l
week
p
respect
increas
baselin
week
p
mean
score
valid
sgrq
improv
week
baselin
p
earli
trial
promis
futur
investig
mechan
antimicrobi
worka
antimicrobi
immun
modul
bothi
warrant
recent
molecular
genet
immunolog
studi
independ
laboratori
support
associ
sarcoidosi
microbi
antigen
particularli
mycobacteria
propionibacteria
find
among
american
sarcoidosi
subject
strongli
associ
mycobacteria
among
japanes
sarcoidosi
subject
propionibacteria
epidemiolog
studi
indic
sarcoidosi
morbid
mortal
increas
impetu
current
sarcoidosi
research
translat
strong
basic
research
investig
innov
therapeut
impact
sarcoidosi
pathogenesi
hope
lead
cure
progress
date
strongli
support
advanc
toward
goal
